Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens

Earlier decades' interest in psychedelic drugs such as LSD prompted both heavy regulation and continued informal use, and a later rediscovery of 3,4-methylenedioxymethamphetamine (MDMA) raised questions about how some newer compounds fit existing pharmacological categories. Ande Rson and colleagues note that MDMA and related substituted amphetamines (for example MDA) produce subjective effects—reduced anxiety, lowered defensiveness, enhanced affect and empathy—that differ qualitatively from the classic sensory and perceptual disruptions of serotonergic hallucinogens such as LSD or DOM. This apparent mismatch between subjective human effects, structure-activity expectations for substituted amphetamines, and emerging biochemical data motivated a re-evaluation of how these compounds should be classified. The study sets out to test the hypothesis that MDMA and structurally related molecules (notably MBDB) are mechanistically distinct from both classic hallucinogens and conventional stimulants, and thus merit recognition as a separate pharmacological class. To address this, the researchers combined structure–activity reasoning with biochemical assays (release and reuptake measurements in synaptosomal preparations), stereoisomer comparisons, and behavioural pharmacology in animals, supplemented by preliminary human observations of subjective effects. The overall aim was to characterise mechanisms of action that could explain the unique clinical and experiential profile and to propose an appropriate taxonomic label for the class.

The investigators used a structure–activity series approach: closely related molecules (MDA, MDMA, MBDB and various stereoisomers) were synthesised or obtained and compared across biochemical and behavioural assays to infer mechanism. Collaboration with other chemists (including Peyton Jacob and Alexander Shulgin) supported synthesis and preliminary human observations for MBDB. Biochemical pharmacology relied primarily on rat brain synaptosomes. Synaptosomes—isolated nerve terminal preparations that retain many presynaptic functions—were incubated with tritium-labelled neurotransmitters (serotonin, dopamine, norepinephrine) to measure both drug-induced transmitter release and inhibition of uptake. Release assays recorded rapid transmitter efflux after drug addition, while uptake-inhibition experiments determined the concentration required to reduce uptake to half (IC50) as a relative potency measure. The authors report comparing isomers and multiple compounds, and summarise results in tables referenced in the text; the extracted text does not provide the numeric IC50 values. Behavioural pharmacology employed drug discrimination in rats, a standard model in which animals are trained to distinguish an injected training drug (here LSD tartrate) from saline. Substitution tests then determine whether test compounds produce an LSD-like stimulus. The team also used published animal work from other laboratories (for example discrimination trained with DOM) to triangulate results. Human data cited in the article comprise descriptive clinical reports and a preliminary clinical study of MBDB; the extraction does not clearly report sample sizes or detailed clinical protocols. Statistical methods and sample sizes for the biochemical and behavioural experiments are not clearly described in the extracted text.

Across biochemical assays, a consistent pattern emerged distinguishing entactogen-type compounds from classical hallucinogens and from potent stimulants. In synaptosomal release assays, MDA and MDMA were shown to provoke release of serotonin from rat brain terminals; for MDA both optical isomers released serotonin equally well, whereas for MDMA the S-(+) isomer was roughly equipotent to MDA and the R-(-) isomer was less potent. In uptake-inhibition experiments, MDA, MDMA and MBDB were all potent inhibitors of serotonin reuptake, with the S-(+) isomers typically more active. Findings for dopamine and norepinephrine diverged between compounds. Amphetamine was a very potent inhibitor of dopamine reuptake, and in the authors' assays both amphetamine and MDA/MDMA altered dopamine utilisation. However, MBDB showed virtually no effect on dopamine-utilising neurons, and in preliminary human reports MBDB produced less euphoria than MDMA. For norepinephrine reuptake, MDA, MDMA and MBDB showed inhibitory activity, again with S-(+) isomers generally more potent; amphetamine remained quantitatively stronger on catecholamine measures than the entactogens. By contrast, the hallucinogenic substituted amphetamine DaM (and DOM in other cited work) had negligible activity on reuptake for dopamine, norepinephrine or serotonin in these assays. Behavioural drug-discrimination studies supported the biochemical separation: in rats trained to discriminate LSD from saline, only MDA produced an LSD-like stimulus generalisation; MDMA and MBDB did not substitute for LSD, consistent with human reports that they do not produce classic hallucinatory effects. The collected data thus show that MDMA and MBDB combine potent serotonergic release and reuptake inhibition with limited dopaminergic action (especially for MBDB), a profile distinct from both classic hallucinogens and prototypical stimulants. The extracted text references tables that present quantitative IC50s and release rates, but those specific numerical values are not included in the provided extract.

Ande Rson and colleagues conclude that MDMA and particularly MBDB do not conform to the pharmacological classification of hallucinogens or simply to stimulant drugs. On the basis of structure–activity relationships, biochemical pharmacology (serotonin release and potent serotonin reuptake inhibition), stereoselectivity of isomers, and behavioural data in rats, the authors argue these compounds constitute a distinct pharmacological category. They propose the term entactogens (from Latin and Greek roots meaning to "produce a touching within") to designate drugs whose principal clinical and subjective effects are affect enhancement, empathy and facilitation of psychotherapeutic access to painful emotional material. The authors justify the new class on three grounds: clinicians who have used MDMA report a distinct adjunctive therapeutic utility, animal and human subjective effects do not resemble those of classical hallucinogens, and MDMA/MBDB violate established structure–activity rules for hallucinogenic substituted amphetamines. Uncertainties acknowledged in the text include that some animal data suggest amphetamine-like properties for certain isomers and that the precise role of norepinephrine requires further study. Nevertheless, the evidence presented leads the investigators to propose MBDB as a prototype entactogen and to recommend recognising entactogens as a separate pharmacological category.